NEW YORK CITY, NY / ACCESS Newswire / October 17, 2025 / NEW YORK, NY / ACCESS Newswire / October 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Tvardi Therapeutics, Inc. ("Tvardi Therapeutics, Inc.") (NASDAQ:TVRD) concerning possible violations of federal securities laws.
On October 13, 2025, Tvardi reported data from its Phase 2 REVERT study testing its STAT3 inhibitor drug, TTI-101, to treat patients with idiopathic pulmonary fibrosis (IPF). The company reported that "the study did not meet its goals," as the "[p]reliminary analysis of exploratory efficacy showed no statistically significant differences between placebo and treatment arms." Management also highlighted significant discontinuation rates of more than 56% in both treatment arms compared to only 10.3% in the placebo group.
Following this news, Tvardi’s stock price fell by $34.91 per share to close at $6.69 per share. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
COMTEX_469591746/2457/2025-10-17T14:52:16